263 related articles for article (PubMed ID: 22410633)
1. The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
Smolen JS; Aletaha D; Redlich K
Nat Rev Rheumatol; 2012 Mar; 8(4):235-43. PubMed ID: 22410633
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
Meroni PL; Valesini G
BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
[TBL] [Abstract][Full Text] [Related]
3. Molecular targets of rheumatoid arthritis.
Okamoto H; Hoshi D; Kiire A; Yamanaka H; Kamatani N
Inflamm Allergy Drug Targets; 2008 Mar; 7(1):53-66. PubMed ID: 18473901
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 in rheumatoid arthritis - from the laboratory to the bedside.
Liu X; Teichtahl AJ; Wicks IP
Curr Pharm Des; 2015; 21(17):2187-97. PubMed ID: 25760299
[TBL] [Abstract][Full Text] [Related]
5. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2.
Lorenz HM; Grünke M; Hieronymus T; Antoni C; Nüsslein H; Schaible TF; Manger B; Kalden JR
J Rheumatol; 2000 Feb; 27(2):304-10. PubMed ID: 10685789
[TBL] [Abstract][Full Text] [Related]
6. Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.
Davignon JL; Rauwel B; Degboé Y; Constantin A; Boyer JF; Kruglov A; Cantagrel A
Arthritis Res Ther; 2018 Oct; 20(1):229. PubMed ID: 30314507
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
Taylor PC; Feldmann M
Nat Rev Rheumatol; 2009 Oct; 5(10):578-82. PubMed ID: 19798034
[TBL] [Abstract][Full Text] [Related]
8. Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.
García-Hernández MH; González-Amaro R; Portales-Pérez DP
Immunotherapy; 2014; 6(5):623-36. PubMed ID: 24896630
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
10. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
11. A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.
Pamuk ÖN; Kalyoncu U; Aksu K; Omma A; Pehlivan Y; Çağatay Y; Küçükşahin O; Dönmez S; Çetin GY; Mercan R; Bayındır Ö; Çefle A; Yıldız F; Balkarlı A; Kılıç L; Çakır N; Kısacık B; Öksüz MF; Çobankara V; Onat AM; Sayarlıoğlu M; Öztürk MA; Pamuk GE; Akkoç N
Rheumatol Int; 2016 Jul; 36(7):945-53. PubMed ID: 27221456
[TBL] [Abstract][Full Text] [Related]
12. Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile.
Luchetti MM; Balloni A; Gabrielli A
Curr Drug Saf; 2016; 11(1):22-34. PubMed ID: 26463246
[TBL] [Abstract][Full Text] [Related]
13. Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies.
Chang CM; Hsu YW; Wong HS; Wei JC; Liu X; Liao HT; Chang WC
Dis Markers; 2019; 2019():2364943. PubMed ID: 31360262
[TBL] [Abstract][Full Text] [Related]
14. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis.
Sebbag M; Parry SL; Brennan FM; Feldmann M
Eur J Immunol; 1997 Mar; 27(3):624-32. PubMed ID: 9079801
[TBL] [Abstract][Full Text] [Related]
15. B Lymphocytes in Rheumatoid Arthritis and the Effects of Anti-TNF-α Agents on B Lymphocytes: A Review of the Literature.
Pala O; Diaz A; Blomberg BB; Frasca D
Clin Ther; 2018 Jun; 40(6):1034-1045. PubMed ID: 29801753
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases.
Möller B; Villiger PM
Springer Semin Immunopathol; 2006 Jun; 27(4):391-408. PubMed ID: 16738952
[TBL] [Abstract][Full Text] [Related]
17. Cytokines in rheumatoid arthritis: is it all TNF-alpha?
Miossec P
Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):675-8. PubMed ID: 11502074
[TBL] [Abstract][Full Text] [Related]
18. The pathogenesis of rheumatoid arthritis and the development of therapeutic strategies for the clinical investigation of biologics.
Panayi GS
Agents Actions Suppl; 1995; 47():1-21. PubMed ID: 7785487
[TBL] [Abstract][Full Text] [Related]
19. Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.
Winthrop KL; Iseman M
Nat Rev Rheumatol; 2013 Sep; 9(9):524-31. PubMed ID: 23797309
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis.
Matsumoto I; Zhang H; Yasukochi T; Iwanami K; Tanaka Y; Inoue A; Goto D; Ito S; Tsutsumi A; Sumida T
Arthritis Res Ther; 2008; 10(3):R66. PubMed ID: 18534002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
